High‐level expression of ARID1A predicts a favourable outcome in triple‐negative breast cancer patients receiving paclitaxel‐based chemotherapy
Paclitaxel‐based chemotherapy is a common strategy to treat patients with triple‐negative breast cancer (TNBC). As paclitaxel resistance is still a clinical issue in treating TNBCs, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Her...
Saved in:
| Published in | Journal of cellular and molecular medicine Vol. 22; no. 4; pp. 2458 - 2468 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
John Wiley & Sons, Inc
01.04.2018
John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Paclitaxel‐based chemotherapy is a common strategy to treat patients with triple‐negative breast cancer (TNBC). As paclitaxel resistance is still a clinical issue in treating TNBCs, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Here, we report that an AT‐rich interaction domain 1A (ARID1A) transcript is up‐regulated in paclitaxel‐sensitive TNBC cells but down‐regulated in paclitaxel‐resistant cells upon paclitaxel treatment. Moreover, ARID1A expression was negatively correlated with the IC50 concentration of paclitaxel in the tested TNBC cell lines. Kaplan‐Meier analyses revealed that ARID1A down‐regulation was related to a poorer response to paclitaxel‐based chemotherapy in patients with TNBCs as measured by the recurrence‐free survival probability. The pharmaceutical inhibition with p38MAPK‐specific inhibitor SCIO‐469 revealed that p38MAPK‐related signalling axis regulates ARID1A expression and thereby modulates paclitaxel sensitivity in TNBC cells. These findings suggest that ARID1A could be used as a prognostic factor to estimate the pathological complete response for TNBC patients who decide to receive paclitaxel‐based chemotherapy. |
|---|---|
| AbstractList | Paclitaxel-based chemotherapy is a common strategy to treat patients with triple-negative breast cancer (TNBC). As paclitaxel resistance is still a clinical issue in treating TNBCs, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Here, we report that an AT-rich interaction domain 1A (ARID1A) transcript is up-regulated in paclitaxel-sensitive TNBC cells but down-regulated in paclitaxel-resistant cells upon paclitaxel treatment. Moreover, ARID1A expression was negatively correlated with the IC50 concentration of paclitaxel in the tested TNBC cell lines. Kaplan-Meier analyses revealed that ARID1A down-regulation was related to a poorer response to paclitaxel-based chemotherapy in patients with TNBCs as measured by the recurrence-free survival probability. The pharmaceutical inhibition with p38MAPK-specific inhibitor SCIO-469 revealed that p38MAPK-related signalling axis regulates ARID1A expression and thereby modulates paclitaxel sensitivity in TNBC cells. These findings suggest that ARID1A could be used as a prognostic factor to estimate the pathological complete response for TNBC patients who decide to receive paclitaxel-based chemotherapy.Paclitaxel-based chemotherapy is a common strategy to treat patients with triple-negative breast cancer (TNBC). As paclitaxel resistance is still a clinical issue in treating TNBCs, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Here, we report that an AT-rich interaction domain 1A (ARID1A) transcript is up-regulated in paclitaxel-sensitive TNBC cells but down-regulated in paclitaxel-resistant cells upon paclitaxel treatment. Moreover, ARID1A expression was negatively correlated with the IC50 concentration of paclitaxel in the tested TNBC cell lines. Kaplan-Meier analyses revealed that ARID1A down-regulation was related to a poorer response to paclitaxel-based chemotherapy in patients with TNBCs as measured by the recurrence-free survival probability. The pharmaceutical inhibition with p38MAPK-specific inhibitor SCIO-469 revealed that p38MAPK-related signalling axis regulates ARID1A expression and thereby modulates paclitaxel sensitivity in TNBC cells. These findings suggest that ARID1A could be used as a prognostic factor to estimate the pathological complete response for TNBC patients who decide to receive paclitaxel-based chemotherapy. Paclitaxel‐based chemotherapy is a common strategy to treat patients with triple‐negative breast cancer (TNBC). As paclitaxel resistance is still a clinical issue in treating TNBCs, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Here, we report that an AT‐rich interaction domain 1A (ARID1A) transcript is up‐regulated in paclitaxel‐sensitive TNBC cells but down‐regulated in paclitaxel‐resistant cells upon paclitaxel treatment. Moreover, ARID1A expression was negatively correlated with the IC50 concentration of paclitaxel in the tested TNBC cell lines. Kaplan‐Meier analyses revealed that ARID1A down‐regulation was related to a poorer response to paclitaxel‐based chemotherapy in patients with TNBCs as measured by the recurrence‐free survival probability. The pharmaceutical inhibition with p38MAPK‐specific inhibitor SCIO‐469 revealed that p38MAPK‐related signalling axis regulates ARID1A expression and thereby modulates paclitaxel sensitivity in TNBC cells. These findings suggest that ARID1A could be used as a prognostic factor to estimate the pathological complete response for TNBC patients who decide to receive paclitaxel‐based chemotherapy. Paclitaxel-based chemotherapy is a common strategy to treat patients with triple-negative breast cancer (TNBC). As paclitaxel resistance is still a clinical issue in treating TNBCs, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Here, we report that an AT-rich interaction domain 1A (ARID1A) transcript is up-regulated in paclitaxel-sensitive TNBC cells but down-regulated in paclitaxel-resistant cells upon paclitaxel treatment. Moreover, ARID1A expression was negatively correlated with the IC concentration of paclitaxel in the tested TNBC cell lines. Kaplan-Meier analyses revealed that ARID1A down-regulation was related to a poorer response to paclitaxel-based chemotherapy in patients with TNBCs as measured by the recurrence-free survival probability. The pharmaceutical inhibition with p38MAPK-specific inhibitor SCIO-469 revealed that p38MAPK-related signalling axis regulates ARID1A expression and thereby modulates paclitaxel sensitivity in TNBC cells. These findings suggest that ARID1A could be used as a prognostic factor to estimate the pathological complete response for TNBC patients who decide to receive paclitaxel-based chemotherapy. Paclitaxel‐based chemotherapy is a common strategy to treat patients with triple‐negative breast cancer ( TNBC ). As paclitaxel resistance is still a clinical issue in treating TNBC s, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Here, we report that an AT ‐rich interaction domain 1A ( ARID 1A ) transcript is up‐regulated in paclitaxel‐sensitive TNBC cells but down‐regulated in paclitaxel‐resistant cells upon paclitaxel treatment. Moreover, ARID 1A expression was negatively correlated with the IC 50 concentration of paclitaxel in the tested TNBC cell lines. Kaplan‐Meier analyses revealed that ARID 1A down‐regulation was related to a poorer response to paclitaxel‐based chemotherapy in patients with TNBC s as measured by the recurrence‐free survival probability. The pharmaceutical inhibition with p38 MAPK ‐specific inhibitor SCIO ‐469 revealed that p38 MAPK ‐related signalling axis regulates ARID 1A expression and thereby modulates paclitaxel sensitivity in TNBC cells. These findings suggest that ARID 1A could be used as a prognostic factor to estimate the pathological complete response for TNBC patients who decide to receive paclitaxel‐based chemotherapy. |
| Author | Lin, Hui‐Yu Kuo, Chih‐Jung Lin, Yuan‐Feng Chiu, I‐Jen Chiu, Hui‐Wen Tseng, Ing‐Jy |
| AuthorAffiliation | 5 Division of Nephrology Department of Internal Medicine Shuang Ho Hospital Taipei Medical University New Taipei City Taiwan 1 Graduate Institute of Clinical Medicine College of Medicine Taipei Medical University Taipei Taiwan 3 Department of Veterinary Medicine National Chung Hsing University Taichung Taiwan 2 School of Gerontology Healthy Management College of Nursing Taipei Medical University Taipei Taiwan 4 Division of Breast Surgery and General Surgery Department of Surgery Cardinal Tien Hospital Xindian District, New Taipei City Taiwan |
| AuthorAffiliation_xml | – name: 3 Department of Veterinary Medicine National Chung Hsing University Taichung Taiwan – name: 1 Graduate Institute of Clinical Medicine College of Medicine Taipei Medical University Taipei Taiwan – name: 5 Division of Nephrology Department of Internal Medicine Shuang Ho Hospital Taipei Medical University New Taipei City Taiwan – name: 2 School of Gerontology Healthy Management College of Nursing Taipei Medical University Taipei Taiwan – name: 4 Division of Breast Surgery and General Surgery Department of Surgery Cardinal Tien Hospital Xindian District, New Taipei City Taiwan |
| Author_xml | – sequence: 1 givenname: Yuan‐Feng surname: Lin fullname: Lin, Yuan‐Feng organization: Taipei Medical University – sequence: 2 givenname: Ing‐Jy surname: Tseng fullname: Tseng, Ing‐Jy organization: Taipei Medical University – sequence: 3 givenname: Chih‐Jung surname: Kuo fullname: Kuo, Chih‐Jung organization: National Chung Hsing University – sequence: 4 givenname: Hui‐Yu surname: Lin fullname: Lin, Hui‐Yu organization: Cardinal Tien Hospital – sequence: 5 givenname: I‐Jen surname: Chiu fullname: Chiu, I‐Jen organization: Taipei Medical University – sequence: 6 givenname: Hui‐Wen orcidid: 0000-0002-5027-390X surname: Chiu fullname: Chiu, Hui‐Wen email: leu3@tmu.edu.tw organization: Taipei Medical University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29392887$$D View this record in MEDLINE/PubMed |
| BookMark | eNpdUstuFDEQHKEg8oALH4AsceGywT2eh-eCtNoACUqEhOBs2Z6eXa889mDPDNkbn8CFH-RL8CZLBPjiVnW5VN2u0-zIeYdZ9hzoOaTzeqv7_hxYWcKj7ARKni-KhhVHhxo448fZaYxbSlkFrHmSHecNa3LO65Ps56VZb359_2FxRkvwdggYo_GO-I4sP11dwJIkqDV6jESSTs5-ClJZJH4ate-RGEfGYAaLScThWo5mRqICyjgSLZ3GQIYEoksCATWa2bh1grQ1o7xFm54pGbEleoO9HzcY5LB7mj3upI347HCfZV_evf28ulxcf3x_tVpeLwZW57BQHKAG2XQl8qJjmlGougorVbes5UpWlBZQSd5oXba1KmqtSlUyYIpy5F3HzrI397rDpHpsdXIZpBVDML0MO-GlEf92nNmItZ9FyauaNjQJvDoIBP91wjiK3kSN1kqHfooCmrTppiponagv_6Nu0y5dGk_kFOqKF1DuBV_87ejByp8fSwS4J3wzFncPfaBinwWxz4K4y4L4sLq5uavYb11xr5w |
| ContentType | Journal Article |
| Copyright | 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. 2018. This work is published under https://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. – notice: 2018. This work is published under https://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P CGR CUY CVF ECM EIF NPM 3V. 7QP 7TK 7X7 7XB 88E 88I 8AO 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI Q9U RC3 7X8 5PM |
| DOI | 10.1111/jcmm.13551 |
| DatabaseName | Wiley Online Library Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Engineering Research Database ProQuest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | LIN et al |
| EISSN | 1582-4934 |
| EndPage | 2468 |
| ExternalDocumentID | PMC5867090 29392887 JCMM13551 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Ministry of Science and Technology, Taiwan funderid: MOST 104‐2320‐B‐038‐061‐MY3; MOST 105‐2320‐B‐038‐021‐MY3 – fundername: Ministry of Science and Technology, Taiwan grantid: MOST 104‐2320‐B‐038‐061‐MY3; MOST 105‐2320‐B‐038‐021‐MY3 |
| GroupedDBID | --- 0R~ 1OC 24P 29K 31~ 36B 3V. 4.4 53G 5GY 5VS 7X7 8-0 8-1 88E 88I 8AO 8FE 8FH 8FI 8FJ 8R4 8R5 AAHHS AAZKR ABUWG ACCFJ ACCMX ACGFS ACGOD ACXQS ADBBV ADKYN ADPDF ADRAZ ADZMN ADZOD AEEZP AENEX AEQDE AFBPY AFKRA AFZJQ AHMBA AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CAG CCPQU COF CS3 D-9 D-I DIK DU5 DWQXO E3Z EBD EBS EJD EMB EMOBN F5P FYUFA GNUQQ GODZA GROUPED_DOAJ HCIFZ HMCUK HYE HZ~ IAO IHR ITC KQ8 LH4 LK8 LW6 M1P M2P M48 M7P O9- OIG OK1 OVD OVEED PIMPY PQQKQ PROAC PSQYO Q2X RNS ROL RPM SV3 TEORI UKHRP WIN ABJNI CGR CUY CVF ECM EIF NPM PHGZT 7QP 7TK 7XB 8FD 8FK AAMMB AEFGJ AGXDD AIDQK AIDYY FR3 K9. P64 PHGZM PJZUB PKEHL PPXIY PQEST PQGLB PQUKI Q9U RC3 7X8 5PM |
| ID | FETCH-LOGICAL-p3721-b81171a9f5e84f3c3016f6e6b7d3d8ba600416a89cc5d7b47cb5b5313b08e8ff3 |
| IEDL.DBID | M48 |
| ISSN | 1582-1838 1582-4934 |
| IngestDate | Thu Aug 21 13:39:01 EDT 2025 Thu Jul 10 18:05:53 EDT 2025 Wed Aug 13 09:57:33 EDT 2025 Thu Apr 03 07:01:50 EDT 2025 Wed Jan 22 16:28:50 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | paclitaxel triple-negative breast cancer ARID1A chemotherapy p38MAPK |
| Language | English |
| License | Attribution 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-p3721-b81171a9f5e84f3c3016f6e6b7d3d8ba600416a89cc5d7b47cb5b5313b08e8ff3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-5027-390X |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1111/jcmm.13551 |
| PMID | 29392887 |
| PQID | 2017684150 |
| PQPubID | 2034150 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5867090 proquest_miscellaneous_1993996407 proquest_journals_2017684150 pubmed_primary_29392887 wiley_primary_10_1111_jcmm_13551_JCMM13551 |
| PublicationCentury | 2000 |
| PublicationDate | April 2018 |
| PublicationDateYYYYMMDD | 2018-04-01 |
| PublicationDate_xml | – month: 04 year: 2018 text: April 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Chichester – name: Hoboken |
| PublicationTitle | Journal of cellular and molecular medicine |
| PublicationTitleAlternate | J Cell Mol Med |
| PublicationYear | 2018 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
| References | 2017; 7 2017; 8 2010; 16 2015; 5 2006; 10 2010; 123 1993; 85 2010; 124 2014; 27 2008; 14 2012; 103 1996; 13 2013; 8 2009; 119 2013; 182 2016; 37 2012; 31 1996; 56 2016; 12 2014; 135 2001; 60 2015; 26 2015; 136 2013; 12 2011; 71 2017; 34 2010; 330 2014; 15 2016; 20 2000; 60 2009; 6 2014; 9 2014; 74 2009; 2 2009; 19 1996; 2 2005; 11 2003; 21 2011; 121 |
| References_xml | – volume: 60 start-page: 290 year: 2001 end-page: 301 article-title: Selective potentiation of paclitaxel (taxol)‐induced cell death by mitogen‐activated protein kinase kinase inhibition in human cancer cell lines publication-title: Mol Pharmacol – volume: 7 start-page: 1350 year: 2017 end-page: 1371 article-title: Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators publication-title: Am J Cancer Res – volume: 27 start-page: 255 year: 2014 end-page: 261 article-title: ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high‐grade endometrial carcinomas publication-title: Mod Pathol – volume: 74 start-page: 2465 year: 2014 end-page: 2475 article-title: SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability publication-title: Cancer Res – volume: 6 start-page: 239 year: 2009 end-page: 240 article-title: The UCSC cancer genomics browser publication-title: Nat Methods – volume: 121 start-page: 2750 year: 2011 end-page: 2767 article-title: Identification of human triple‐negative breast cancer subtypes and preclinical models for selection of targeted therapies publication-title: J Clin Invest – volume: 10 start-page: 241 year: 2006 end-page: 252 article-title: Selective killing of oncogenically transformed cells through a ROS‐mediated mechanism by beta‐phenylethyl isothiocyanate publication-title: Cancer Cell – volume: 19 start-page: 1461 year: 2009 end-page: 1464 article-title: Investigations of SCIO‐469‐like compounds for the inhibition of p38 MAP kinase publication-title: Bioorg Med Chem Lett – volume: 56 start-page: 1253 year: 1996 end-page: 1255 article-title: Taxol induces bcl‐2 phosphorylation and death of prostate cancer cells publication-title: Cancer Res – volume: 21 start-page: 959 year: 2003 end-page: 962 article-title: Are anthracycline‐taxane regimens the new standard of care in the treatment of metastatic breast cancer? publication-title: J Clin Oncol – volume: 9 start-page: e106131 year: 2014 article-title: Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells publication-title: PLoS ONE – volume: 31 start-page: 1073 year: 2012 end-page: 1085 article-title: P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5‐fluorouracil: implication in resistance publication-title: Oncogene – volume: 2 start-page: 72 year: 1996 end-page: 79 article-title: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis publication-title: Nat Med – volume: 12 start-page: 931 year: 2013 end-page: 947 article-title: Modulation of oxidative stress as an anticancer strategy publication-title: Nat Rev Drug Discov – volume: 136 start-page: E359 year: 2015 end-page: E386 article-title: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 publication-title: Int J Cancer – volume: 2 start-page: 18 year: 2009 article-title: PrognoScan: a new database for meta‐analysis of the prognostic value of genes publication-title: BMC Med Genomics – volume: 8 start-page: e74250 year: 2013 article-title: SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis publication-title: PLoS ONE – volume: 15 start-page: 2427 year: 2014 end-page: 2431 article-title: Triple negative breast cancer publication-title: Asian Pac J Cancer Prev – volume: 85 start-page: 892 year: 1993 end-page: 897 article-title: The lifetime risk of developing breast cancer publication-title: J Natl Cancer Inst – volume: 34 start-page: S27 issue: Suppl 1 year: 2017 end-page: S30 article-title: Mechanisms of resistance of chemotherapy in early‐stage triple negative breast cancer (TNBC) publication-title: Breast – volume: 11 start-page: 7490 year: 2005 end-page: 7498 article-title: Curcumin suppresses the paclitaxel‐induced nuclear factor‐kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice publication-title: Clin Cancer Res – volume: 26 start-page: 117 year: 2015 end-page: 122 article-title: Nab‐paclitaxel for the management of triple‐negative metastatic breast cancer: a case study publication-title: Anticancer Drugs – volume: 13 start-page: 1359 year: 1996 end-page: 1365 article-title: Overexpression of c‐erbB‐2/neu in breast cancer cells confers increased resistance to Taxol via mdr‐1‐independent mechanisms publication-title: Oncogene – volume: 330 start-page: 228 year: 2010 end-page: 231 article-title: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma publication-title: Science – volume: 60 start-page: 2464 year: 2000 end-page: 2472 article-title: A role for the p38 mitogen‐activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents publication-title: Cancer Res – volume: 103 start-page: 913 year: 2012 end-page: 920 article-title: GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER‐negative breast cancer publication-title: Cancer Sci – volume: 123 start-page: 725 year: 2010 end-page: 731 article-title: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients publication-title: Breast Cancer Res Treat – volume: 20 start-page: 1064 year: 2016 end-page: 1070 article-title: Advance in the study on p38 MAPK mediated drug resistance in leukemia publication-title: Eur Rev Med Pharmacol Sci – volume: 135 start-page: 611 year: 2014 end-page: 623 article-title: Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer publication-title: Int J Cancer – volume: 124 start-page: 723 year: 2010 end-page: 732 article-title: Preoperative concurrent paclitaxel‐radiation in locally advanced breast cancer: pathologic response correlates with five‐year overall survival publication-title: Breast Cancer Res Treat – volume: 182 start-page: 1163 year: 2013 end-page: 1170 article-title: The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma publication-title: Am J Pathol – volume: 31 start-page: 2090 year: 2012 end-page: 2100 article-title: An integrated genomic approach identifies ARID1A as a candidate tumor‐suppressor gene in breast cancer publication-title: Oncogene – volume: 16 start-page: 681 year: 2010 end-page: 690 article-title: Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation publication-title: Clin Cancer Res – volume: 5 start-page: 752 year: 2015 end-page: 767 article-title: ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors publication-title: Cancer Discov – volume: 71 start-page: 6718 year: 2011 end-page: 6727 article-title: ARID1A, a factor that promotes formation of SWI/SNF‐mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers publication-title: Cancer Res – volume: 12 start-page: 4067 year: 2016 end-page: 4071 article-title: ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatin publication-title: Exp Ther Med – volume: 14 start-page: 458 year: 2008 end-page: 470 article-title: Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis publication-title: Cancer Cell – volume: 8 start-page: 1 year: 2017 end-page: 8 article-title: Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer publication-title: J Cancer – volume: 119 start-page: 2171 year: 2009 end-page: 2183 article-title: RCP is a human breast cancer‐promoting gene with Ras‐activating function publication-title: J Clin Invest – volume: 37 start-page: 15275 year: 2016 end-page: 15282 article-title: Serum microRNA‐21 expression as a prognostic and therapeutic biomarker for breast cancer patients publication-title: Tumour Biol |
| SSID | ssj0036139 |
| Score | 2.3080425 |
| Snippet | Paclitaxel‐based chemotherapy is a common strategy to treat patients with triple‐negative breast cancer (TNBC). As paclitaxel resistance is still a clinical... Paclitaxel-based chemotherapy is a common strategy to treat patients with triple-negative breast cancer (TNBC). As paclitaxel resistance is still a clinical... Paclitaxel‐based chemotherapy is a common strategy to treat patients with triple‐negative breast cancer ( TNBC ). As paclitaxel resistance is still a clinical... |
| SourceID | pubmedcentral proquest pubmed wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 2458 |
| SubjectTerms | Adult Aged Antineoplastic Combined Chemotherapy Protocols - pharmacology ARID1A Breast cancer Cell Line, Tumor Chemotherapy Disease-Free Survival DNA-Binding Proteins Drug Resistance, Neoplasm - genetics Female Gene Expression Regulation, Neoplastic - drug effects Humans Indoles - pharmacology Kaplan-Meier Estimate Middle Aged Nuclear Proteins - genetics Original p38 Mitogen-Activated Protein Kinases - genetics p38MAPK Paclitaxel Paclitaxel - administration & dosage Paclitaxel - adverse effects Patients Transcription Transcription Factors - genetics Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - pathology triple‐negative breast cancer |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEA4-ELyIb9cXETwJhe32lZ5kURcV1oO4sLeSpIkuuO267cp68yd48Q_6S5xJs1VRvLVNk5LOJJlJvvmGkGPNpI-06Y7HWej4qWg5AiOWW3hEFHk64iaKv3sTXvb8637QtxtuhYVVzuZEM1GnucQ9cnDSXTwzAvvldPTkYNYoPF21KTTmySJSlyGkK-rXDpcHS1VsKUkNekcOh5jnIXD_Mid_oyK_W6tmuemskhVrJ9J2Jdg1MqeydbJUZY582SDviM_4eH17RMwPVVMLZ81ormn79urcbVN4lA5kWVBONX-G9jBIiuaTEvqr6CCj5Rg32aGRTN0b-m8qEKFeUomaMKaWcrWgMCmqAW48wCOJpN5T9QjVcAFMKQh9aKO4XjZJr3Nxd3bp2AwLzghk4ToCw0xdHutAMV97EkZ7qEMViij1UiZ4iHRcIWexlEEaCT-SIhAwaj3RZIpp7W2RhSzP1A6hCGPF_H7IB-hz1-OyJdLYj0UsAhU0wwbZn_3yxA6TIvkSaoMc1cWg4HhqwTOVT4oEEYbglIHj2SDblYSSUcXEkYCtErdgmmyQ6Ifs6heQPPtnSTZ4MCTaAUPmOvjuiZFyXaN2ikBZEqMsyfVZt2uudv_vwx5ZhhtW4Xr2yUI5nqgDMFlKcWj08hN_DfIU priority: 102 providerName: ProQuest – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEA6LIngR39YXETwJBftOwcvig3VhRURhbyVJE13YbZdtV9abP8GLf9Bf4kzaLS568VbSJCWdmWSSfPMNIaeaSR9p022Ps9D2U-HaAiOWXbwiijwdcRPF37sLO09-tx_0W-RiHgtT8UM0B25oGWa-RgPnovhp5HI0wqwNGD-9jLG1yJzv-vfzediDhSo2bKngQ4Lispqc1OB4mrZ_OZa_8ZE__Vaz8Nysk7XaY6TtSsQbpKWyTbJS5ZB82yKfiNT4ev8YIvqHqlkNbM1ormn74fbKaVMoSgeyLCinmr9CfxguRfNpCUNWdJDRcoLH7dBJpp4NETgViFUvqUSdmNCafLWgMD2qAR5BQJFEeu-ZGkIzXApTCuIf1fFcb9vk6eb68bJj17kW7DFIxbEFBpw6PNaBYr72JNh9qEMViij1UiZ4iMRcIWexlEEaCT-SIhBgv544Z4pp7e2QpSzP1B6hCGjFTH_IDOhzx-PSFWnsxyIWgQrOQ4sczn95UhtMkYAfgleC4J5a5KR5DaqO9xc8U_m0SBBrCNsz2IJaZLeSUDKuODkS8FpiFyZMi0QLsmsqII324pts8GLotAOGHHbw3TMj5aZFsz0CZUmMsiTdy17PPO3_p_IBWYXhsQrvc0iWyslUHYErU4pjo7Hfngr1Hw priority: 102 providerName: Wiley-Blackwell |
| Title | High‐level expression of ARID1A predicts a favourable outcome in triple‐negative breast cancer patients receiving paclitaxel‐based chemotherapy |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjcmm.13551 https://www.ncbi.nlm.nih.gov/pubmed/29392887 https://www.proquest.com/docview/2017684150 https://www.proquest.com/docview/1993996407 https://pubmed.ncbi.nlm.nih.gov/PMC5867090 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pa9swFH50LYNdxtb9aLouaLDTwKOJZUs-jJF2LW0hpZR5hF2MJEttIHG6xCnJbX_CLv0H-5f0PdkxC91pF9vYloz9PllP0ve-B_DRScNJNj0IlYwDnutuoCliuUtLRCJ0Qvko_v55fJLys0E02IBV_s76A87-ObSjfFLpdPR58Wv5FRv8l4aVY8Zjyt9AkdRb2CMJaqB93qwmhNhlJV43Fb1JhLCsZUrXy5IscILegmfXPfY2H5Mm_3ZmfW90_AKe124k61V2fwkbttiGp1ViyeUruCP6xv3vPyOiBDG7qNmuBZs41rs8_dbpMTyVD005Y4o5dYv1UQwVm8xLhKBlw4KVU5qDx0oKe-XVwZkmAnvJDAFlympF1hnDf6Yd0rwEnjKk-b2wIyxG_WPOEBPjOshr-RrS46PvhydBnYAhuEFTdQJNUagdlbjISu5Cgz-D2MU21iIPc6lVTGpdsZKJMVEuNBdGRxobdaj3pZXOhW9gs5gUdgcYsVwp_R_JBXLVCZXp6jzhiU50ZKP9uAV7q0-erUCQoXNC64Tos7bgQ3MZ8U-LGqqwk_ksIwIijtlwXNqCt5WFsptKqCNb2bMFYs12zQ2krb1-pRhee43tSJKwHT73k7dyU6IZMyFuMo-b7Oyw3_dHu__9mHfwDN9VVoygPdgsp3P7Hp2dUrfhSZdf4FYMRBu2ej_SnynuD47OLy7bfgKh7bH-AG0QCaM |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB6VrRBcKn7L0gJGggtSpCbOj3NA1dIf7bbdFapaqbdgOw6s1E2WTbZ0b32EXngNHoonYcZJFioQt96iOHEU-7M9Y3_zDcCbTGifZNMdLkXo-KnyHEURyx4dEUU8i6SN4h-Owv6pf3AWnK3AjzYWhmiV7ZxoJ-q00LRHjk66S2dGaL9sT786lDWKTlfbFBo1LA7N4hu6bOX7wS7271vP29872ek7TVYBZ4rfdx1FoZWujLPACD_jGhEeZqEJVZTyVCgZkgRVKEWsdZBGyo-0ChQilastYUSWcaz3Dqz6HF2ZDqx-2Bt9PG7nfo6LY9yIoFq-kJ5MKLNE4P7LgP2bh_mnfWwXuP0HsNZYpqxXQ-khrJj8Edytc1UuHsN3YoT8vLo-J5YRM5cNgTZnRcZ6x4Ndt8fwVjrWVckky-QF1kdhWayYV9jCho1zVs1oWx8ryc1nKzjOFHHiK6YJezPWiLyWDKdhM6atDrylSUb80pzja7TkpgxhNmnixhZP4PRWWv8pdPIiN8-AEXGWMgqSAqEvXS61p9LYj1WsAhNshV3YbJs8aQZmmfyGURdeL4txSNE5icxNMS8T4jSiG4iubhfW6x5KprX2R4LWUezhxNyF6EbfLR8gue6bJfn4i5XtDgRp5eF339leXr6xdMMQLIkFS3KwMxzaq-f__4dXcK9_MjxKjgajww24jwWiZhVtQqeazc0LNJgq9bJBKYNPtz0wfgF8kjAg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFD4aQyBu0PgvDDAS3CBFLHF-nAs0VSvVutEJISb1LtiODZXWpDTptt7xCNzwMjwOT8I5ThqYQNztLnIaJ7U_2-fY3_kOwHMrdEiy6R6XIvbCXAWeoojlgI6IEm4T6aL4x0fx_nF4MIkmG_BjHQtDtMr1nOgm6rzUtEeOTrpPZ0Zov7yyLS3i3WC4O__iUQYpOmldp9NoIHJoVmfovlWvRwPs6xdBMHzzYW_fazMMeHP8Ft9TFGbpy9RGRoSWa0R7bGMTqyTnuVAyJjmqWIpU6yhPVJhoFSlELVc7wghrOdZ7Ba4mPPJpjCWTztnjuEymrRyqYw7p2YxyTET-v0zZvxmZf1rKbqkbbsHN1kZl_QZUt2DDFLfhWpO1cnUHvhM35OfXbyfEN2LmvKXSFqy0rP9-NPD7DIvyqa4rJpmVp1gfBWixclljWxs2LVi9oA1-rKQwn5z0OFPEjq-ZJhQuWCv3WjGckM2UNj2wSJOg-Lk5wcdo8c0ZAm7WRpCt7sLxpbT9PdgsysI8AEYUWsotSFqEofS51IHK0zBVqYpMtBP3YHvd5Fk7RKvsN6B68Ky7jYOLTkxkYcpllRG7ER1CdHp7cL_poWzeqIBkaCelAU7RPUgu9F33AxLuvninmH52At6RINU8fO9L18vdE51DhmDJHFiyg73x2F09_P9_eArXcThkb0dHh4_gBpaLhl60DZv1Ymkeo-VUqycOogw-XvaY-AXxCzLw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High%E2%80%90level+expression+of+ARID1A+predicts+a+favourable+outcome+in+triple%E2%80%90negative+breast+cancer+patients+receiving+paclitaxel%E2%80%90based+chemotherapy&rft.jtitle=Journal+of+cellular+and+molecular+medicine&rft.au=Lin%2C+Yuan%E2%80%90Feng&rft.au=Tseng%2C+Ing%E2%80%90Jy&rft.au=Kuo%2C+Chih%E2%80%90Jung&rft.au=Lin%2C+Hui%E2%80%90Yu&rft.date=2018-04-01&rft.pub=John+Wiley+and+Sons+Inc&rft.issn=1582-1838&rft.eissn=1582-4934&rft.volume=22&rft.issue=4&rft.spage=2458&rft.epage=2468&rft_id=info:doi/10.1111%2Fjcmm.13551&rft_id=info%3Apmid%2F29392887&rft.externalDocID=PMC5867090 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1582-1838&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1582-1838&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1582-1838&client=summon |